|
Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a worldwide project that provides reliable clinical data for the research of pathology principle, prevention and treatment of Alzheimer’s disease (AD). Multiple research groups contribute their findings of the biological markers to the understanding of the progression of Alzheimer’s disease in the human brain. The project enlists scientists and executives from the National Institutes of Health, the Food and Drug Administration, drug and medical-imaging companies, universities and nonprofit groups.〔 The initiative's defining characteristic is the commitment by all groups to publish and relinquish ownership of their data and findings as soon as possible, i.e., without waiting for the completion of their research. Collaborators also agreed to forgo any patent opportunities.〔 The current focus is to measure the levels of certain proteins in the cerebrospinal fluid of people who may have Alzheimer's or may go on to develop it. ==Primary aims== * Understand the pathology of AD by using biomarkers and diagnose AD at its earliest stage * Provide clinical trials results from worldwide research to support the new methods in intervening, preventing and treating AD〔A snapshot of the Alzheimer's Disease Neuroimaging Initiative Detail Only Available,Weiner, Michael W,Aging Health. August, 2012, Vol. 8 Issue 4, p337, 4 p〕 * Continue and improve the sharing of database 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Alzheimer's Disease Neuroimaging Initiative」の詳細全文を読む スポンサード リンク
|